Vaccines (Jun 2022)

Natural History of <i>Sudan ebolavirus</i> to Support Medical Countermeasure Development

  • Caroline Carbonnelle,
  • Marie Moroso,
  • Delphine Pannetier,
  • Sabine Godard,
  • Stéphane Mély,
  • Damien Thomas,
  • Aurélie Duthey,
  • Ophélie Jourjon,
  • Orianne Lacroix,
  • Béatrice Labrosse,
  • Hervé Raoul,
  • Karen L. Osman,
  • Francisco J. Salguero,
  • Yper Hall,
  • Carol L. Sabourin,
  • Michael J. Merchlinsky,
  • James P. Long,
  • Lindsay A. Parish,
  • Daniel N. Wolfe

DOI
https://doi.org/10.3390/vaccines10060963
Journal volume & issue
Vol. 10, no. 6
p. 963

Abstract

Read online

Sudan ebolavirus (SUDV) is one of four members of the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which is characterized by hemorrhagic fever and a high case fatality rate. While licensed therapeutics and vaccines are available in limited number to treat infections of Zaire ebolavirus, there are currently no effective licensed vaccines or therapeutics for SUDV. A well-characterized animal model of this disease is needed for the further development and testing of vaccines and therapeutics. In this study, twelve cynomolgus macaques (Macaca fascicularis) were challenged intramuscularly with 1000 PFUs of SUDV and were followed under continuous telemetric surveillance. Clinical observations, body weights, temperature, viremia, hematology, clinical chemistry, and coagulation were analyzed at timepoints throughout the study. Death from SUDV disease occurred between five and ten days after challenge at the point that each animal met the criteria for euthanasia. All animals were observed to exhibit clinical signs and lesions similar to those observed in human cases which included: viremia, fever, dehydration, reduced physical activity, macular skin rash, systemic inflammation, coagulopathy, lymphoid depletion, renal tubular necrosis, hepatocellular degeneration and necrosis. The results from this study will facilitate the future preclinical development and evaluation of vaccines and therapeutics for SUDV.

Keywords